A Study to Assess the Bioequivalence of Darunavir When Co-Administrated With Cobicistat Under Fed and Fasted Conditions
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the single-dose pharmacokinetics and bioequivalence
of darunavir 800 mg when administered as a fixed dose combination relative to 2 x 400 mg
tablets of the commercial tablet formulation, in the presence of 150 mg cobicistat, (under
fed and fasted conditions) in healthy participants.